Elbaz P
Fondation Rothschild, Paris, France.
Acta Otolaryngol Suppl. 1988;460:143-8.
One hundred and seventeen adult patients suffering from vestibular vertigo were treated in a multicentre double-blind study with flunarizine (10 mg before sleeping) or betahistine dichlorhydrate (8 mg 3 times daily). The study took 2 months. The results revealed that flunarizine is significantly more active against attacks of vertigo and associated symptoms (mainly neurovegetative disorders, anxiety and headaches). The global superiority of flunarizine was confirmed by both the evaluation by the investigators and the patient. Significantly fewer patients treated with flunarizine reported side effects or interrupted the trial therapy prematurely. This study confirms the value of the calcium antagonist flunarizine in the treatment of vestibular vertigo.
117名患有前庭性眩晕的成年患者参与了一项多中心双盲研究，他们被分为两组，一组服用氟桂利嗪（睡前10毫克），另一组服用二盐酸倍他司汀（每日3次，每次8毫克）。该研究为期2个月。结果显示，氟桂利嗪在对抗眩晕发作及相关症状（主要是植物神经功能紊乱、焦虑和头痛）方面明显更有效。研究者和患者的评估均证实了氟桂利嗪的整体优势。服用氟桂利嗪的患者报告副作用或过早中断试验治疗的人数明显更少。这项研究证实了钙拮抗剂氟桂利嗪在治疗前庭性眩晕方面的价值。
